Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Enlivex Therapeutics Ltd. | -0.580% | -3.804% | -69.744% | 43.902% | 190.164% | -21.681% | -78.282% |
| Oramed Pharmaceuticals | -1.100% | -2.914% | 3.824% | 104.406% | 51.134% | 27.879% | -79.684% |
| Formycon AG | 2.590% | -3.138% | -0.963% | -29.313% | -27.515% | -73.003% | -66.204% |